PYXS vs. RANI, MGNX, ADCT, ACET, STTK, ABVX, SPRY, IMNM, IRON, and CNTA
Should you be buying Pyxis Oncology stock or one of its competitors? The main competitors of Pyxis Oncology include Rani Therapeutics (RANI), MacroGenics (MGNX), ADC Therapeutics (ADCT), Adicet Bio (ACET), Shattuck Labs (STTK), ABIVAX Société Anonyme (ABVX), ARS Pharmaceuticals (SPRY), Immunome (IMNM), Disc Medicine (IRON), and Centessa Pharmaceuticals (CNTA). These companies are all part of the "pharmaceutical preparations" industry.
Rani Therapeutics (NASDAQ:RANI) and Pyxis Oncology (NASDAQ:PYXS) are both small-cap medical companies, but which is the better investment? We will contrast the two companies based on the strength of their risk, dividends, profitability, media sentiment, valuation, institutional ownership, analyst recommendations, community ranking and earnings.
In the previous week, Pyxis Oncology had 3 more articles in the media than Rani Therapeutics. MarketBeat recorded 5 mentions for Pyxis Oncology and 2 mentions for Rani Therapeutics. Pyxis Oncology's average media sentiment score of 1.25 beat Rani Therapeutics' score of 0.43 indicating that Rani Therapeutics is being referred to more favorably in the media.
Rani Therapeutics' return on equity of -38.99% beat Pyxis Oncology's return on equity.
Rani Therapeutics presently has a consensus target price of $12.20, indicating a potential upside of 170.51%. Pyxis Oncology has a consensus target price of $8.80, indicating a potential upside of 132.19%. Given Pyxis Oncology's higher probable upside, equities research analysts clearly believe Rani Therapeutics is more favorable than Pyxis Oncology.
30.2% of Rani Therapeutics shares are owned by institutional investors. Comparatively, 39.1% of Pyxis Oncology shares are owned by institutional investors. 53.3% of Rani Therapeutics shares are owned by insiders. Comparatively, 9.3% of Pyxis Oncology shares are owned by insiders. Strong institutional ownership is an indication that large money managers, hedge funds and endowments believe a stock will outperform the market over the long term.
Rani Therapeutics has a beta of 0.33, indicating that its stock price is 67% less volatile than the S&P 500. Comparatively, Pyxis Oncology has a beta of 1.45, indicating that its stock price is 45% more volatile than the S&P 500.
Rani Therapeutics has higher revenue and earnings than Pyxis Oncology. Rani Therapeutics is trading at a lower price-to-earnings ratio than Pyxis Oncology, indicating that it is currently the more affordable of the two stocks.
Rani Therapeutics received 3 more outperform votes than Pyxis Oncology when rated by MarketBeat users. However, 80.00% of users gave Pyxis Oncology an outperform vote while only 76.67% of users gave Rani Therapeutics an outperform vote.
Summary
Pyxis Oncology beats Rani Therapeutics on 8 of the 15 factors compared between the two stocks.
Get Pyxis Oncology News Delivered to You Automatically
Sign up to receive the latest news and ratings for PYXS and its competitors with MarketBeat's FREE daily newsletter.
This chart shows the number of new MarketBeat users adding PYXS and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.
This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.
Pyxis Oncology Competitors List
Related Companies and Tools
